Overview

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Status:
Unknown status

Trial end date:
2020-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies. The study will also examine the body's immune response to EGFR(V)-EDV-Dox and assess if it is effective in the treatment of patients with recurrent glioblastoma multiforme (GBM).

Phase:

Phase 1

Details

Lead Sponsor:

Engeneic Pty Limited

Collaborators:

Johns Hopkins University
The Johns Hopkins Hospital

Treatments:

Doxorubicin
Liposomal doxorubicin